Windyga J, Rzymkiewicz L, Lopaciuk S
Samodzielna Pracownia Krzepniecia Krwi i Hemostazy Instytutu Hematologii i Transfuzjologii w Warszawie.
Acta Haematol Pol. 1996;27(1):27-31.
The development of antibodies to factor VIII (circulating anticoagulant, factor VIII inhibitor) is a serious complication following substitution therapy in patients with hemophilia A. These antibodies are rarely specific of human factor VIII, tending to cross-react to a variable extent with factor VIII from other species. Their neutralizing activity is usually weaker against porcine than human factor VIII. In this study, anti-human and anti-porcine factor VIII antibodies (Ab) were measured in 41 patients with severe hemophilia A. The anti-human Ab titers ranged from 0.5 to 1200 BU/ml, and the anti-porcine Ab titers ranged from 0 to 170 BU/ml. The median cross-reactivity was 28% (mean 28.9 +/- 17.2%, range 0-75%). Of the 24 patients with anti-human Ab titers > 5 BU/ml, 11 (46%) had a low anti-porcine Ab level (< or = 5 BU/ml). These patients could be treated effectively with porcine factor VIII concentrate (Hyate: C).
血友病A患者在替代治疗后产生抗凝血因子VIII抗体（循环抗凝剂，VIII因子抑制剂）是一种严重的并发症。这些抗体很少对人VIII因子具有特异性，往往会与其他物种的VIII因子发生不同程度的交叉反应。它们对猪VIII因子的中和活性通常比对人VIII因子弱。在本研究中，对41例重度血友病A患者检测了抗人及抗猪VIII因子抗体（Ab）。抗人Ab滴度范围为0.5至1200 BU/ml，抗猪Ab滴度范围为0至170 BU/ml。交叉反应的中位数为28%（平均值28.9 +/- 17.2%，范围0 - 75%）。在24例抗人Ab滴度>5 BU/ml的患者中，11例（46%）抗猪Ab水平较低（≤5 BU/ml）。这些患者可用猪VIII因子浓缩物（Hyate: C）进行有效治疗。
